Correction: Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study.

Correction: Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study.

[This corrects the article DOI: 10.1371/journal.pone.0198777.].

Bibliographic Details
Main Authors:	Myriam Calle Rubio, Joan B Soriano, José Luis López-Campos, Juan J Soler-Cataluña, Bernardino Alcázar Navarrete, José Miguel Rodríguez González-Moro, Marc Miravitlles, Miriam Barrecheguren, Manuel E Fuentes Ferrer, Juan Luis Rodriguez Hermosa, EPOCONSUL Study
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2019-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC6372200?pdf=render

Similar Items

Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study.
by: Myriam Calle Rubio, et al.
Published: (2018-01-01)

Detection of Alpha-1 Antitrypsin Levels in Chronic Obstructive Pulmonary Disease in Respiratory Clinics in Spain: Results of the EPOCONSUL 2021 Audit
by: Myriam Calle Rubio, et al.
Published: (2024-02-01)

Variability in adherence to clinical practice guidelines and recommendations in COPD outpatients: a multi-level, cross-sectional analysis of the EPOCONSUL study
by: Myriam Calle Rubio, et al.
Published: (2017-12-01)

Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study
by: Calle Rubio M, et al.
Published: (2017-01-01)

Assessing the clinical practice in specialized outpatient clinics for chronic obstructive pulmonary disease: Analysis of the EPOCONSUL clinical audit.
by: Myriam Calle Rubio, et al.
Published: (2019-01-01)

The concept of control of COPD in clinical practice
by: Soler-Cataluña JJ, et al.
Published: (2014-12-01)

Determinants in the Underdiagnosis of COPD in Spain—CONOCEPOC Study
by: Myriam Calle Rubio, et al.
Published: (2022-05-01)

Smoking and COPD Knowledge in the General Spanish Population: A CONOCEPOC Study
by: Juan Luis Rodríguez Hermosa, et al.
Published: (2023-07-01)

Utility of Transient Elastography for the Screening of Liver Disease in Patients with Alpha1-Antitrypsin Deficiency
by: Mònica Pons, et al.
Published: (2021-04-01)

Nine controversial questions about augmentation therapy for alpha-1 antitrypsin deficiency: a viewpoint
by: Marc Miravitlles, et al.
Published: (2023-12-01)

Demographic and clinical characteristics of patients with α1-antitrypsin deficiency genotypes PI*ZZ and PI*SZ in the Spanish registry of EARCO
by: María Torres-Durán, et al.
Published: (2022-09-01)

Unravelling young COPD and pre-COPD in the general population
by: Borja G. Cosío, et al.
Published: (2023-02-01)

Is a previous diagnosis of asthma a reliable criterion for asthma–COPD overlap syndrome in a patient with COPD?
by: Barrecheguren M, et al.
Published: (2015-09-01)

Severe COVID-19 Illness and α1-Antitrypsin Deficiency: COVID-AATD Study
by: Juan Luis Rodríguez Hermosa, et al.
Published: (2023-02-01)

Validation of clinical control in COPD as a new tool for optimizing treatment
by: Soler-Cataluña JJ, et al.
Published: (2018-11-01)

Diagnosis of alpha-1 antitrypsin deficiency: a population-based study
by: Barrecheguren M, et al.
Published: (2016-05-01)

COVID-19’s impact on care practice for alpha-1-antitrypsin deficiency patients
by: Myriam Calle Rubio, et al.
Published: (2023-01-01)

Application of a diagnostic algorithm for the rare deficient variant Mmalton of alpha-1-antitrypsin deficiency: a new approach
by: Belmonte I, et al.
Published: (2016-10-01)

Testing for Vitamin D in High-Risk COPD in Outpatient Clinics in Spain: A Cross-Sectional Analysis of the VITADEPOC Study
by: Myriam Calle Rubio, et al.
Published: (2022-03-01)

Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
by: Marc Miravitlles, et al.
Published: (2022-12-01)

Correction: Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
by: Marc Miravitlles, et al.
Published: (2023-02-01)

New variants of alpha-1-antitrypsin: structural simulations and clinical expression
by: Angel Gonzalez, et al.
Published: (2022-12-01)

Soporte telefónico al paciente con EPOC en tiempos de la COVID-19
by: José Luis Lopez-Campos, et al.
Published: (2020-07-01)

What have we learned from observational studies and clinical trials of mild to moderate COPD?
by: Miriam Barrecheguren, et al.
Published: (2018-09-01)

Evaluating the impact of morning symptoms in COPD using the Capacity of Daily Living during the Morning (CDLM) questionnaire
by: Núñez A, et al.
Published: (2018-11-01)

Association between circulating alpha-1 antitrypsin polymers and lung and liver disease
by: Alexa Núñez, et al.
Published: (2021-09-01)

Alpha-1 antitrypsin deficiency: outstanding questions and future directions
by: María Torres-Durán, et al.
Published: (2018-07-01)

Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT)
by: Esquinas C, et al.
Published: (2018-03-01)

Prevalence of alpha-1 antitrypsin deficiency and allele frequency in patients with COPD in Brazil
by: Rodrigo Russo, et al.

Prevalence of α1-antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review
by: Ignacio Blanco, et al.
Published: (2020-07-01)

Correction to: Association between circulating alpha-1 antitrypsin polymers and lung and liver disease
by: Alexa Núñez, et al.
Published: (2021-11-01)

Validation and development of an immunonephelometric assay for the determination of alpha-1 antitrypsin levels in dried blood spots from patients with COPD
by: Laura Russo Zillmer, et al.
Published: (2013-09-01)

Diagnosis of Alpha-1 Antitrypsin Deficiency (AATD) in Primary Care
by: Miriam Barrecheguren, et al.
Published: (2024-04-01)

Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence
by: Franck F. Rahaghi, et al.
Published: (2017-05-01)

Rare alpha-1-antitrypsin variants: are they really so rare?
by: Francisco Rodriguez-Frias, et al.
Published: (2012-04-01)

Trends in Diagnosis of Alpha-1 Antitrypsin Deficiency Between 2015 and 2019 in a Reference Laboratory
by: Belmonte I, et al.
Published: (2020-10-01)

Gene and miRNA expression profiles in PBMCs from patients with severe and mild emphysema and PiZZ alpha1-antitrypsin deficiency
by: Esquinas C, et al.
Published: (2017-11-01)

A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease
by: Marc Miravitlles, et al.
Published: (2017-11-01)

COPD in individuals with the PiMZ alpha-1 antitrypsin genotype
by: Haitham S. Al Ashry, et al.
Published: (2017-10-01)

Identification and distribution of COPD phenotypes in clinical practice according to Spanish COPD Guidelines: the FENEPOC study
by: Calle Rubio M, et al.
Published: (2017-08-01)